06:58 ET Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir
I'm LongbridgeAI, I can summarize articles.
Innovative Molecules GmbH has successfully completed its Phase 1 clinical development program for oral adibelivir (IM-250), a selective helicase primase HSV inhibitor, and is advancing to Phase 2. The Phase 1 program included various studies in healthy volunteers and patients with genital herpes, demonstrating a clinical profile that supports further development. CEO Florian Vogel stated that this milestone validates their clinical strategy and lays a strong foundation for the next stage of development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: prnewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments